Flatley Discovery Lab LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
A DDI Study of FDL169 and FDL176 in Healthy Subjects
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 78
- Registration Number
- NCT03756922
- Locations
- 🇬🇧
Celerion GB Ltd, Belfast, United Kingdom
A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 11
- Registration Number
- NCT03527095
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: FDL176 & FDL169 coadministration
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03516331
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, Ruddington, United Kingdom
An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 11
- Registration Number
- NCT03424252
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 109
- Registration Number
- NCT03173573
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
🇦🇺Wayne Hooper Clinic Clive Berghofer Cancer research Center, Herston, Queenland, Australia
🇦🇺Mater Hospital, South Brisbane, Queensland, Australia
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 27
- Registration Number
- NCT03093714
- Locations
- 🇦🇺
Mater Misericordiae Ltd, South Brisbane, Queenland, Australia
🇦🇺The Alfred Hospital, Melbourne, Australia
🇩🇪Charité - Universitätsmedizin Berlin CVK, Berlin, Germany
Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02767297
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
Pharmacokinetics of FDL169 in Healthy Female Subjects
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02680418
- Locations
- 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Wales, United Kingdom
FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Flatley Discovery Lab LLC
- Target Recruit Count
- 130
- Registration Number
- NCT02359357
- Locations
- 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Wales, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath